Trial reportDiabetes, obesity & metabolism2006
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.
Trial report in Diabetes, obesity & metabolism, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 127 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus
An Open Label Study to Examine the Long Term Effect on Glucose Control (HbA1c) and Safety and Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes Mellitus
Who cites it
127 citing papers in PubMed, 3 syntheses or guidelines pooled it, 418 citations in OpenAlex.
- The Use of Exenatide in Managing Markers of Cardiovascular Risk in Patients with Type 2 Diabetes: A Systematic Review.International journal of environmental research and public health · 2016Pooled it
- Glucagon-like peptide analogues for type 2 diabetes mellitus.The Cochrane database of systematic reviews · 2011 · on this mapPooled it
- Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes.Cardiovascular diabetology · 2011Pooled it
- Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: A randomized, double-blind, placebo-controlled trial.Metabolism: clinical and experimental · 2018Trial
- Trial
- Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study.Cardiovascular diabetology · 2015 · on this mapTrial
- Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes.Cardiovascular diabetology · 2015Trial
- Effect of exenatide, sitagliptin, or glimepiride on β-cell secretory capacity in early type 2 diabetes.Diabetes care · 2014Trial
- Alterations in energy balance following exenatide administration.Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme · 2012 · on this mapTrial
- Investigation of the haemodynamic effects of exenatide in healthy male subjects.British journal of clinical pharmacology · 2012Trial
- Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers.Vascular health and risk management · 2012Trial
- Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes.Diabetes care · 2012Trial
- A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.Diabetologia · 2007 · on this mapTrial
- Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes.Health and quality of life outcomes · 2006Trial
- A salute to innovation: exenatide in diabetes and obesity drug development at Amylin Pharmaceuticals.Nature metabolism · 2025Article
- Annual Prize Lecture 2024: Endogenous physiological mechanisms as basis for the treatment of obesity and type 2 diabetes.The Journal of physiology · 2024Article
- Article
- Review
- Variants inHeliyon · 2024Article
- Towards Optimal Cardiovascular Health: A Comprehensive Review of Preventive Strategies.Cureus · 2024Review
67 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimExenatide, an incretin mimetic for the adjunct treatment of type 2 diabetes (DM2), reduced A1C and weight in 30-week placebo-controlled trials. This analysis examined the effects of exenatide on glycaemic control and weight over an 82-week period in patients with DM2 unable to achieve adequate glycaemic control with sulphonylurea (SU) and/or metformin (MET).
methodsThis interim analysis is of 314 patients who received exenatide in the 30-week placebo-controlled trials and subsequently in 52 weeks of open-label uncontrolled extension studies for 82 weeks of exenatide in total. Patients continued their SU and/or MET regimens throughout.
resultsPatients completed 82 weeks of exenatide treatment [n = 314, 63% M, age 56 +/- 10 years, weight 99 +/- 21 kg, body mass index 34 +/- 6 kg/m2, A1C 8.3 +/- 1.0% (mean +/- SD)]. Reduction in A1C from baseline to week 30 [-0.9 +/- 0.1% (mean +/- SE)] was sustained to week 82 (-1.1 +/- 0.1%), with 48% of patients achieving A1C < or = 7% at week 82. At week 30, exenatide reduced body weight (a secondary endpoint) from baseline (-2.1 +/- 0.2 kg), with progressive reduction at week 82 (-4.4 +/- 0.3 kg). Similar results were observed for the intent-to-treat population (n = 551), with reductions in A1C and weight at week 82 of -0.8 +/- 0.1% and -3.5 +/- 0.2 kg respectively. The 82-week completer cohort showed statistically significant improvement in some cardiovascular risk factors. The most frequent adverse events were generally mild-to-moderate nausea and hypoglycaemia.
conclusionIn summary, 82 weeks of adjunctive exenatide treatment in patients with DM2 treated with SU and/or MET resulted in sustained reduction in A1C and progressive reduction in weight, as well as improvement in some cardiovascular risk factors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.